Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Has Average Price Target of $155.56 According to Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have earned an average recommendation of “Moderate Buy” from the fifteen research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $155.56.

A number of research analysts have recently commented on the stock. Robert W. Baird boosted their price target on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. Leerink Partners dropped their target price on shares of Mirum Pharmaceuticals from $154.00 to $140.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th. Citigroup boosted their price target on shares of Mirum Pharmaceuticals from $184.00 to $194.00 and gave the stock a “buy” rating in a research note on Wednesday, November 11th. TD Cowen upped their price target on shares of Mirum Pharmaceuticals from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Finally, Raymond James Financial restated a “strong-buy” rating and set a $189.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 4th.

Check Out Our Latest Research Report on MIRM

Mirum Pharmaceuticals Price Performance

MIRM opened at $95.51 on Friday. Mirum Pharmaceuticals has a twelve month low of $63.23 and a twelve month high of $130.00. The company’s 50-day moving average price is $88.23 and its two-hundred day moving average price is $98.22. The company has a current ratio of 2.07, a quick ratio of 1.98 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.38). The business had revenue of $185.72 million during the quarter, compared to analysts’ expectations of $178.07 million. Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. Mirum Pharmaceuticals’s revenue for the quarter was up 39.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.05 EPS. As a group, equities analysts predict that Mirum Pharmaceuticals will post -1.47 EPS for the current year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 658 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total transaction of $65,800.00. Following the transaction, the senior vice president directly owned 616 shares of the company’s stock, valued at approximately $61,600. The trade was a 51.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Laura Brege sold 14,167 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $94.21, for a total value of $1,334,673.07. Following the completion of the transaction, the director directly owned 15,703 shares of the company’s stock, valued at $1,479,379.63. This represents a 47.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 64,825 shares of company stock worth $6,160,873 over the last quarter. Corporate insiders own 8.32% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in Mirum Pharmaceuticals in the second quarter worth approximately $513,945,000. Secure Asset Management LLC bought a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at approximately $4,466,000. Rice Hall James & Associates LLC purchased a new position in shares of Mirum Pharmaceuticals during the second quarter valued at about $12,956,000. Jupiter Topco LLC bought a new stake in shares of Mirum Pharmaceuticals in the second quarter worth about $691,672,000. Finally, Man Group plc bought a new stake in shares of Mirum Pharmaceuticals in the second quarter worth about $4,353,000.

Mirum Pharmaceuticals Company Profile

(Get Free Report)

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.

Recommended Stories

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.